Rainbow Childrens Medicare cash flow

Latest FY26

Cash from operations: ₹420cr+6.1% on FY25
Capital spending: ₹216cr+48.6% on FY25
Free cash flow: ₹203cr−18.7% on FY25
Cash from financing: −₹147cr−₹118 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	151	138	112	90.3
	—	0.0	0.0	0.0	3.0
	—	76.6	72.5	59.1	55.2
	—	0.0	−14.4	−20.4	−29.8
	—	0.0	0.0	0.0	−0.4
	—	0.0	−28.1	−5.9	−0.5
	—	2.9	−1.3	0.0	0.0
	—	−0.1	0.0	0.0	0.1
	—	−12.8	0.7	2.7	6.1
	—	−24.7	−7.9	0.0	0.0
	—	0.1	0.0	−7.5	0.0
	—	−14.1	−3.6	−5.2	−3.9
	—	−31.3	−7.8	−16.5	−23.0
	—	0.0	0.0	−5.7	10.8
	—	−15.7	−10.6	0.0	0.0
	—	16.7	9.5	2.7	20.0
	—	10.8	−1.9	−0.1	−1.6
	—	3.7	5.6	0.0	0.0
Cash from operating activities
	371	358	330	295	282
	—	163	151	115	126
	—	521	481	410	408
	—	102	85.6	88.6	80.9
	—	420	396	321	327
Cash from investing activities
	—	216	146	354	141
	—	1.3	0.1	0.1	0.0
	—	0.0	0.0	0.0	0.2
	—	203	0.0	0.0	0.0
	—	0.0	0.0	13.5	9.3
	—	0.0	0.0	0.0	0.4
	—	11.6	22.2	23.1	16.1
	—	148	−144	90.4	−350
	—	−259	−268	−226	−465
Cash from financing activities
	—	0.0	0.1	0.0	280
	—	0.0	0.0	0.0	39.8
	—	18.0	87.3	72.5	0.0
	—	—	—	0.0	59.4
	—	77.6	0.0	0.0	3.2
	—	30.5	30.5	30.8	20.3
	—	−21.3	0.0	1.5	−13.9
	—	−147	−118	−102	143
	—	13.6	10.1	−6.8	5.4
	—	13.6	10.1	−6.8	5.4
	—	33.9	20.3	10.1	15.4
Reference items
	575	544	490	429	396
	31.6%	32.0%	32.3%	33.1%	33.8%
	203	203	250	−32.2	186
	—	126	—	—	—
	₹20.01	₹20.01	₹24.62	−₹3.17	₹18.31
	59.82×	—	—	—	—
	—	1.49×	1.62×	1.47×	1.54×
	—	102	85.6	88.6	80.9
	—	77.6	—	—	3.2

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

RAINBOW₹1,196.80

Rainbow Childrens Medicare Ltd.

· Pharma & Health

₹ CrorePeersAPOLLOHOSP FORTIS KIMS POLYMED PFIZER ONESOURCE JUBLPHARMA VIJAYAMcap ₹12,155 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	90.3	112.1	138.4	150.6	—
+ Impairment Loss / (Reversal)	3.0	0.0	0.0	0.0	—
+ Finance Costs	55.2	59.1	72.5	76.6	—
+ Interest Income	-29.8	-20.4	-14.4	0.0	—
+ Dividend Income	-0.4	0.0	0.0	0.0	—
+ Fair Value (Gains) / Losses	-0.5	-5.9	-28.1	0.0	—
+ Share-based Payments	0.0	0.0	-1.3	2.9	—
+ Unrealised FX (Gain) / Loss	0.1	0.0	0.0	-0.1	—
+ Other Non-cash Items	6.1	2.7	0.7	-12.8	—
+ Other — Cash Effects are Investing / Financing	0.0	0.0	-7.9	-24.7	—
+ Other Reconciling Items	0.0	-7.5	0.0	0.1	—
Changes in Working Capital
+ Inventories	-3.9	-5.2	-3.6	-14.1	—
+ Trade Receivables — Current	-23.0	-16.5	-7.8	-31.3	—
+ Other Financial Assets — Current	10.8	-5.7	0.0	0.0	—
+ Other Current Assets	0.0	0.0	-10.6	-15.7	—
+ Trade Payables — Current	20.0	2.7	9.5	16.7	—
+ Other Financial Liabilities — Current	-1.6	-0.1	-1.9	10.8	—
+ Provisions — Current	0.0	0.0	5.6	3.7	—
Cash from Operating Activities
Profit Before Tax (per I/S)	281.8	294.8	330.0	358.2	370.8
+ Total Adjustments (incl. Working Capital)	126.3	115.2	151.3	163.0	—
Cash from Operations (pre-tax)	408.1	410.0	481.3	521.2	—
+ Income Taxes Paid	80.9	88.6	85.6	101.5	—
Cash from Operating Activities	327.2	321.4	395.7	419.7	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	141.3	353.6	145.7	216.5	—
+ Disp of Fixed Assets	0.0	0.1	0.1	1.3	—
+ Disp of Investment Property	0.2	0.0	0.0	0.0	—
+ Acq of Subsidiaries / Businesses (net)	0.0	0.0	0.0	203.2	—
+ Loans & Advances Repaid	9.3	13.5	0.0	0.0	—
+ Dividends Received — Investing	0.4	0.0	0.0	0.0	—
+ Interest Received — Investing	16.1	23.1	22.2	11.6	—
+ Other Inflows / (Outflows) — Investing	-349.7	90.4	-144.4	148.1	—
Cash from Investing Activities	-465.2	-226.5	-267.8	-258.6	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	280.0	0.0	0.1	0.0	—
+ Repayment of Borrowings	39.8	0.0	0.0	0.0	—
+ Payment of Lease Liabilities	0.0	72.5	87.3	18.0	—
+ Payment of Finance Lease Liabilities	59.4	0.0	—	—	—
+ Interest Paid	3.2	0.0	0.0	77.6	—
+ Dividends Paid	20.3	30.8	30.5	30.5	—
+ Other Inflows / (Outflows) — Financing	-13.9	1.5	0.0	-21.3	—
Cash from Financing Activities	143.4	-101.8	-117.7	-147.4	—
Net Changes in Cash (pre-FX)	5.4	-6.8	10.1	13.6	—
Net Changes in Cash	5.4	-6.8	10.1	13.6	—
Closing Cash	15.4	10.1	20.3	33.9	—
Reference Items
EBITDA	396.4	428.9	489.9	544.2	575.2
EBITDA Margin %	33.78	33.07	32.32	31.95	31.60
Free Cash Flow (CFO − Capex)	185.9	-32.2	250.0	203.2	203.2
Free Cash Flow to Equity	—	—	—	125.6	—
Free Cash Flow per Basic Share	18.31	-3.17	24.62	20.01	20.01
Price to Free Cash Flow	—	—	—	—	59.82
Cash Flow to Net Income	1.54	1.47	1.62	1.49	—
Cash Paid for Taxes	80.9	88.6	85.6	101.5	—
Cash Paid for Interest	3.2	—	—	77.6	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.